COYA
Coya Therapeutics, Inc.NASDAQHealthcare$4.01-1.72%ClosedMarket Cap: $67.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.57
P/S
8.53
EV/EBITDA
-1.03
DCF Value
$5.22
FCF Yield
-16870.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.7%
Operating Margin
-255.0%
Net Margin
-267.1%
ROE
-64.3%
ROA
-42.5%
ROIC
-46.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $4.0M | 231.3% | $-4.3M | $-5.7M | $-0.34 | — |
| FY 2025 | $7.9M | 99.7% | $-20.3M | $-21.2M | $-1.27 | — |
| Q3 2025 | $3.6M | 99.8% | $-1.9M | $-2.1M | $-0.13 | — |
| Q2 2025 | $163.6K | 95.8% | $-6.4M | $-6.1M | $-0.36 | — |
| Q1 2025 | $257.9K | -1921.9% | $-7.7M | $-7.3M | $-0.44 | — |
| Q4 2024 | $2.0K | -99154.1% | $-4.1M | $-2.9M | $-0.18 | — |
| FY 2024 | $3.6M | -233.9% | $-17.2M | $-14.9M | $-0.98 | — |
| Q3 2024 | $0.00 | -Infinity% | $-4.5M | $-4.0M | $-0.26 | — |
| Q2 2024 | $3.4M | -33.3% | $-3.2M | $-2.9M | $-0.19 | — |
| Q1 2024 | $126.8K | -2374.1% | $-5.5M | $-5.1M | $-0.35 | — |
| Q4 2023 | $6.0M | 73.2% | $1.8M | $1.3M | $0.12 | — |
| FY 2023 | $6.0M | 8.3% | $-7.9M | $-8.0M | $-0.79 | — |